Injectable bioresorbable conductive hydrogels for multimodal brain tumor electroimmunotherapy
(2025) In Nature Communications 16(1).- Abstract
Current electrode technologies are too rigid for safe and effective delivery of electrotherapy in the brain, and patients with glioblastoma continue to face a devastating prognosis, with median survival stalled at 15 months despite intensive treatment with surgery, radiation, and chemotherapy. But these conventional approaches potentially compromise immune function, underscoring the urgent need for therapies that activate, rather than suppress, the immune system. Therefore, we introduce injectable conductive hydrogels engineered to match the softness of brain tissue while exhibiting electrical conductivities up to three orders of magnitude higher than any previously reported injectable hydrogels. They can be implanted through minimally... (More)
Current electrode technologies are too rigid for safe and effective delivery of electrotherapy in the brain, and patients with glioblastoma continue to face a devastating prognosis, with median survival stalled at 15 months despite intensive treatment with surgery, radiation, and chemotherapy. But these conventional approaches potentially compromise immune function, underscoring the urgent need for therapies that activate, rather than suppress, the immune system. Therefore, we introduce injectable conductive hydrogels engineered to match the softness of brain tissue while exhibiting electrical conductivities up to three orders of magnitude higher than any previously reported injectable hydrogels. They can be implanted through minimally invasive syringe capillaries as narrow as 30 µm-avoiding brain tissue damage-and via convection-enhanced delivery (CED) or endovascular catheters, the latter potentially eliminating the need for open brain surgery. Additionally, it can drape a resection cavity to eliminate residual tumor cells. In human glioblastoma tumors in the chicken chorioallantoic membrane model, implantation of the electrode using CED, followed by irreversible electroporation, obliterated tumors within three days. Other injection techniques impaired tumor growth, induced immunogenic cell death, and a robust infiltration of helper and cytotoxic T cells, alongside macrophages, highlighting the immune-activating and tumor-targeting capabilities.
(Less)
- author
- organization
-
- MultiPark: Multidisciplinary research focused on Parkinson's disease
- Chemical Biology and Therapeutics (research group)
- Department of Experimental Medical Science
- LU Profile Area: Light and Materials
- LTH Profile Area: Nanoscience and Semiconductor Technology
- NanoLund: Centre for Nanoscience
- Particle and nuclear physics
- Tumor microenvironment
- Neurosurgery
- StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
- Department of Clinical Sciences, Lund
- Stem Cell Center
- LTH Profile Area: Food and Bio
- LTH Profile Area: Engineering Health
- Pure and Applied Biochemistry
- Department of Chemistry
- Lund Laser Centre, LLC
- LTH Profile Area: Photon Science and Technology
- eSSENCE: The e-Science Collaboration
- LUCC: Lund University Cancer Centre
- Epilepsy Center
- Centre for Analysis and Synthesis
- publishing date
- 2025-11-03
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Hydrogels/chemistry, Animals, Brain Neoplasms/therapy, Humans, Glioblastoma/therapy, Immunotherapy/methods, Cell Line, Tumor, Electric Conductivity, Injections, Electrochemotherapy/methods, Chick Embryo, Chickens, Mice, Combined Modality Therapy, Electroporation, Cancer therapy, Materials science
- in
- Nature Communications
- volume
- 16
- issue
- 1
- article number
- 9702
- pages
- 12 pages
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:41184309
- ISSN
- 2041-1723
- DOI
- 10.1038/s41467-025-65785-x
- language
- English
- LU publication?
- yes
- additional info
- © 2025. The Author(s).
- id
- e5812ebc-0237-463e-9b40-4f36efdcec98
- date added to LUP
- 2025-11-12 16:22:15
- date last changed
- 2025-11-14 15:14:39
@article{e5812ebc-0237-463e-9b40-4f36efdcec98,
abstract = {{<p>Current electrode technologies are too rigid for safe and effective delivery of electrotherapy in the brain, and patients with glioblastoma continue to face a devastating prognosis, with median survival stalled at 15 months despite intensive treatment with surgery, radiation, and chemotherapy. But these conventional approaches potentially compromise immune function, underscoring the urgent need for therapies that activate, rather than suppress, the immune system. Therefore, we introduce injectable conductive hydrogels engineered to match the softness of brain tissue while exhibiting electrical conductivities up to three orders of magnitude higher than any previously reported injectable hydrogels. They can be implanted through minimally invasive syringe capillaries as narrow as 30 µm-avoiding brain tissue damage-and via convection-enhanced delivery (CED) or endovascular catheters, the latter potentially eliminating the need for open brain surgery. Additionally, it can drape a resection cavity to eliminate residual tumor cells. In human glioblastoma tumors in the chicken chorioallantoic membrane model, implantation of the electrode using CED, followed by irreversible electroporation, obliterated tumors within three days. Other injection techniques impaired tumor growth, induced immunogenic cell death, and a robust infiltration of helper and cytotoxic T cells, alongside macrophages, highlighting the immune-activating and tumor-targeting capabilities.</p>}},
author = {{Yadav, Amit Singh and Aydemir, Umut and Hellman, Karin and Ekström, Peter and Mousa, Abdelrazek H and Li, Jiaxin and Shameem, Muhammad Anwar and Dicko, Cedric and Bengzon, Johan and Ek, Fredrik and Hjort, Martin and Olsson, Roger}},
issn = {{2041-1723}},
keywords = {{Hydrogels/chemistry; Animals; Brain Neoplasms/therapy; Humans; Glioblastoma/therapy; Immunotherapy/methods; Cell Line, Tumor; Electric Conductivity; Injections; Electrochemotherapy/methods; Chick Embryo; Chickens; Mice; Combined Modality Therapy; Electroporation; Cancer therapy; Materials science}},
language = {{eng}},
month = {{11}},
number = {{1}},
publisher = {{Nature Publishing Group}},
series = {{Nature Communications}},
title = {{Injectable bioresorbable conductive hydrogels for multimodal brain tumor electroimmunotherapy}},
url = {{http://dx.doi.org/10.1038/s41467-025-65785-x}},
doi = {{10.1038/s41467-025-65785-x}},
volume = {{16}},
year = {{2025}},
}
